Medigene Management

Management criteria checks 1/4

Medigene's CEO is Selwyn Ho, appointed in Jul 2022, has a tenure of 2.25 years. directly owns 0.42% of the company’s shares, worth CHF121.98K. The average tenure of the management team and the board of directors is 1.9 years and 7.2 years respectively.

Key information

Selwyn Ho

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.3yrs
CEO ownership	0.4%
Management average tenure	1.9yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Selwyn Ho's remuneration changed compared to Medigene's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€16m
Mar 31 2024	n/a	n/a	-€16m
Dec 31 2023	n/a	n/a	-€16m
Sep 30 2023	n/a	n/a	-€23m
Jun 30 2023	n/a	n/a	-€29m
Mar 31 2023	n/a	n/a	-€19m
Dec 31 2022	€612k	€157k	-€8m

Compensation vs Market: Insufficient data to establish whether Selwyn's total compensation is reasonable compared to companies of similar size in the Swiss market.

Compensation vs Earnings: Insufficient data to compare Selwyn's compensation with company performance.

CEO

Selwyn Ho (53 yo)

2.3yrs

Tenure

€612,472

Compensation

Dr. Selwyn Ho, MBBS, serves as Chief Executive Officer & Chairman of the Executive Management Board at Medigene AG since July 25, 2022. He served as Chief Business Officer at Connect Biopharma Holdings Lim...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Selwyn Ho	CEO & Chairman of Executive Management Board	2.3yrs	€612.47k	0.42% CHF 122.0k
Dolores Schendel	Chief Scientific Officer	10.4yrs	€624.00k	no data
Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	no data	€20.00k	no data
Birger Kohlert	Chief Financial Officer	no data	no data	no data
Pamela Keck	Vice President of Investor Relations & Corporate Communications	1.6yrs	no data	no data
Kirsty Crame	VP and Head of Clinical Research & Development	1.6yrs	no data	no data

1.9yrs

Average Tenure

Experienced Management: MDG1's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	7.2yrs	€20.00k	no data
Anthony Man	Independent Member of the Supervisory Board	3.8yrs	€21.00k	no data
Antoinette Hiebeler-Hasner	Independent Deputy Chairwomen of the Supervisory Board	8.2yrs	€36.00k	no data
Gerd Zettlmeissl	Independent Chairman of the Supervisory Board	7.4yrs	€46.00k	no data
Ronald Scott	Independent Member of the Supervisory Board	7.4yrs	€24.00k	no data
Frank Mathias	Independent Member of the Supervisory Board	6.4yrs	€30.00k	0.071% CHF 20.7k
Peter Krammer	Member of Scientific Advisory Board	7.2yrs	no data	no data
Lawrence Samelson	Member of Scientific Advisory Board	7.2yrs	no data	no data
Micha Drukker	Member of Scientific Advisory Board	7.2yrs	no data	no data
Freda Stevenson	Member of Scientific Advisory Board	7.2yrs	no data	no data
Jolanda de Vries	Member of Scientific Advisory Board	7.2yrs	no data	no data

7.2yrs

Average Tenure

68yo

Average Age

Experienced Board: MDG1's board of directors are considered experienced (7.2 years average tenure).

Medigene Management

Management criteria checks 1/4

Key information

Recent management updates

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Executive Changes

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Recent updates

Medigene AG Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities At Cell 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings released: €0.66 loss per share (vs €0.34 loss in FY 2022)

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Forecast to breakeven in 2022

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Forecast to breakeven in 2022

Medigene Confirms Revenue Guidance for 2021

No longer forecast to breakeven

Medigene AG Provides Earnings Guidance for the Year 2021

Advisor has left the company

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial

Earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age